Clinical Trials Browser

Phase 3 × camrelizumab × Tumor-Agnostic × Clear all

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Phase 3 Completed

543 enrolled 13 charts

Neoplasm Metastasis